RxDoctor Payments Data

Gregory Osmundson, MD

Ophthalmology · Sioux Falls, SDNPI 1255391801

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,265 of the $1,931 with a category attached, or 65.5%. 12 manufacturers reported payments, led by Alcon at 45.6% of the total. Reporting peaked in 2024 at $1,035 and has fallen 57.3% since, to $443 in 2025.

$1,931in general payments, 2019–2025

Across 37 payments — averaging $52.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$882
  • NEW World Medical,inc.$284
  • AbbVie$244
  • Amgen$120
  • Harrow Eye, LLC$108
  • Johnson & Johnson Surgical Vision, Inc.$106
  • plus $188 from 6 others

What the payments were for

  • Travel & lodging$66634%
  • Food & beverage$1,26566%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,931 in reported general payments places this provider in the 65th percentile of 52 ophthalmology providers in South Dakota.

See all ophthalmology providers in South Dakota

Medicare billing

Part B allowed, 2024
$157,912
Medicare patients
221
Services billed
810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate255$7,568
Ketorolac Tromethamine253$3,633
LumiganBimatoprost11$2,727
Ofloxacin221$2,668
Latanoprost146$1,108
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat53$797
Timolol Maleate29$388
Brimonidine Tartrate38$209
Dorzolamide Hcl15$178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$244$2,72711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 52 ophthalmology providers in South Dakota.

Other ophthalmology in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →